Charlotte Brunsdon

Charlotte Brunsdon is a counsel in Goodwin’s Antitrust and Competition practice. Charlotte advises on a wide range of complex competition, foreign subsidies regulation (FSR) and foreign direct investment (FDI) matters. She has direct experience of working at the UK’s Competition and Markets Authority.

She has advised leading businesses on EU, UK, and international merger control, foreign subsidies, and foreign investment matters, antitrust investigations, cartels and compliance. Her clients include leading companies in the life sciences, technology, and private equity industries, amongst others. Charlotte has presented to the ABA Antitrust Section on developments in antitrust in healthcare.

Charlotte’s experience includes advising leading businesses in sectors which include: pharmaceuticals, life sciences and med tech; private equity, buyouts and acquisitions, private investment funds; real estate, propsci and proptech; and tech, AI, and machine learning.

Representative experience includes advising:

• Silo AI in its acquisition by Advanced Micro Devices, Inc.
• TA Associates on its acquisition, with Warburg Pincus, of Epassi
• TA Associates on its acquisition, with Warburg Pincus, of Exercite Group
• Eidos Therapeutics on grant of an exclusive license to Bayer for a pipeline therapy for the treatment of transthyretin amyloidosis, for $310 million upfront plus milestone payments
• Tata Communications on its $100 million acquisition of Kaleyra
• iRobot Corporation in its proposed acquisition by Amazon.com, Inc. for approximately $1.7 billion
• SunMed Group on its definitive agreement to acquire the respiratory health business of Avanos Medical, Inc.
• 30 Technology on the sale of its antimicrobial nitric oxide platform in certain applications to Convatec Group Plc (LSE: CTEC) for up to £176 million (including milestones and royalties)
• Advising various clients on potential applicability of the UK National Security and Investment Act to Series A and Seed Funding processes
• Nimbus Therapeutics on the sale of its Allosteric Tyk2 inhibitor program to Takeda for $4 billion upfront and $6 billion total
• Triton on the sale of German cloud-based hosting and digital marketing services company dogado to Cinven and OTPP
• Ritchie Bros on its acquisition of IAA, Inc for $7.3 billion
• Pfizer Inc. on several transactions, including its acquisition of Biohaven (~$12 billion) and Global Blood Therapeutics (~$5.4 billion) and others*
• Pfizer on the sale of its Hospira Infusion Business to ICU Medical, valued at $1 billion*
• Medtronic on its $1.64 billion acquisition of Mazor Robotics Ltd*
• Medtronic in relation to the European aspects of an acquisition in the medical technology sector valued at over $1 billion*
• Wright Medical Group N.V. on its acquisition by Stryker Corp. in a transaction with a total enterprise value of approximately $5.4 billion*
• TPG on its $4 billion sale of Wind River to Aptiv*
• New Mountain Capital, on the sale of Cytel Inc, to Nordic Capital and Astorg*
• Google in relation to multi-jurisdictional competition law investigations*
• Baring Private Equity Asia on its US$1.8 billion sale, alongside the Shanghai-based Bright Food Group, of British breakfast cereal brand Weetabix to U.S.-based cereal company, Post Holdings*
• BlueCoat on its sale, valued at over $4 billion, to Symantec*
• Exponent Private Equity on the sale of Pattonair to Platinum Equity*
• CCMP on the acquisition of commercial pool equipment manufacturer, Hayward Industries*

* Denotes experience prior to moving to Goodwin.

• Author, “Is There An Antitrust Enforcement Gap for “Killer Acquisitions”? An EU Perspective on the Pharmaceuticals Industry,” ABA Antitrust Healthcare Chronicle, December 2020
• Co-Author, “United Kingdom” GLI – Merger Control 2020, May 2020
• Moderator and Presenter, “International Antitrust Developments in Healthcare and Pharmaceuticals: December 2018 through March 2019”, ABA Section of Antitrust Law, April 16, 2019
• Panelist, “What I’ve Learned So Far,” Legal Cheek Panel, June 27, 2019